Fatty Acid Oxidation Disorders Detected by Newborn Screening: Clinical, Biochemical and Genetic Spectrum in a Single‐Center Cohort

ABSTRACT Newborn screening (NBS) has significantly improved early detection and survival in fatty acid oxidation disorders (FAODs). However, the expanding phenotypic spectrum challenges prognostic stratification, and long‐term morbidity remains incompletely characterized. We conducted an observational, retrospective, single‐center study of patients with FAODs identified through NBS and followed between 2011 and 2024. Clinical, biochemical, genetic, and nutritional data were extracted from medical records. Correlations between biochemical markers, enzymatic activity, and clinical outcomes were analyzed. The study was approved by the Research Committee of the Instituto de Investigación, Hospital 12 de Octubre (Madrid). Sixty‐five patients were included: 42 MCADD, 11 VLCADD, 5 LCHADD, 2 CPT1D, 3 CPT2D, 1 CACTD, and 1 MADD. Median age at last follow‐up was 7.2 years (range 0.4–13.6). Two patients died during follow‐up (overall mortality 3.1%). In MCADD, confirmatory C8 concentrations correlated with residual enzyme activity and metabolic decompensations. In VLCADD, NBS and confirmatory C14:1 levels correlated with enzyme activity but not with clinical severity. VLCADD showed marked clinical heterogeneity, whereas LCHADD patients had the highest disease burden and required the most intensive nutritional management. Overall, 40% of patients experienced at least one metabolic decompensation, occurring significantly more frequently in LC‐FAOD than in MCADD. Neuropsychological manifestations were observed in 16.9% of patients. In summary, NBS markedly improves survival in FAODs, but morbidity remains substantial, particularly in LC‐FAOD. Current biochemical markers are useful for early risk stratification but remain insufficient to predict long‐term clinical severity. These findings support individualized multidisciplinary follow‐up, including specialized nutritional care and systematic neuropsychological assessment.

Authors

Institutions

Publication Details

Journal
JIMD Reports
Published
2026-10-14
DOI
https://doi.org/10.1002/jmd2.70132
Primary Topic
Metabolism and Genetic Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Fatty Acid Oxidation Disorders Detected by Newborn Screening: Clinical, Biochemical and Genetic Spectrum in a Single‐Center Cohort

Carmen Martin‐Fernández, D. Barrio‐Carreras, Pedro Ruiz‐Sala, Pilar Quijada‐Fraile et al.
JIMD Reports
Metabolism and Genetic Disorders
article

Fatty Acid Oxidation Disorders Detected by Newborn Screening: Clinical, Biochemical and Genetic Spectrum in a Single‐Center Cohort

Carmen Martin‐Fernández, D. Barrio‐Carreras, Pedro Ruiz‐Sala, Pilar Quijada‐Fraile, Luis Miguel García‐Cárdaba, Patricia Alcaide, Elena Martín‐Hernández, Patricia Pérez‐Mohand, María Martín‐Cazaña, Berta Zamora Crespo, Teresa Hernández Chamorro
article en

Abstract

ABSTRACT Newborn screening (NBS) has significantly improved early detection and survival in fatty acid oxidation disorders (FAODs). However, the expanding phenotypic spectrum challenges prognostic stratification, and long‐term morbidity remains incompletely characterized. We conducted an observational, retrospective, single‐center study of patients with FAODs identified through NBS and followed between 2011 and 2024. Clinical, biochemical, genetic, and nutritional data were extracted from medical records. Correlations between biochemical markers, enzymatic activity, and clinical outcomes were analyzed. The study was approved by the Research Committee of the Instituto de Investigación, Hospital 12 de Octubre (Madrid). Sixty‐five patients were included: 42 MCADD, 11 VLCADD, 5 LCHADD, 2 CPT1D, 3 CPT2D, 1 CACTD, and 1 MADD. Median age at last follow‐up was 7.2 years (range 0.4–13.6). Two patients died during follow‐up (overall mortality 3.1%). In MCADD, confirmatory C8 concentrations correlated with residual enzyme activity and metabolic decompensations. In VLCADD, NBS and confirmatory C14:1 levels correlated with enzyme activity but not with clinical severity. VLCADD showed marked clinical heterogeneity, whereas LCHADD patients had the highest disease burden and required the most intensive nutritional management. Overall, 40% of patients experienced at least one metabolic decompensation, occurring significantly more frequently in LC‐FAOD than in MCADD. Neuropsychological manifestations were observed in 16.9% of patients. In summary, NBS markedly improves survival in FAODs, but morbidity remains substantial, particularly in LC‐FAOD. Current biochemical markers are useful for early risk stratification but remain insufficient to predict long‐term clinical severity. These findings support individualized multidisciplinary follow‐up, including specialized nutritional care and systematic neuropsychological assessment.

JIMD ReportsVol. 67(6)
Research Institute Hospital 12 de Octubre (ES), Hospital Universitario 12 De Octubre (ES), Instituto de Investigación de Enfermedades Raras (ES), Universidad Autónoma de Madrid (ES)
Good health and well-being
Openalex Percentile: Top 15%
Metabolism and Genetic Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.